Skip to main content

Table 1 Patients characteristics and demographics

From: Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus

  All patients (n = 92) No organ damage SLICC/ACR-DI = 0 (n = 42) Organ damage SLICC/ACR-DI ≥1 (n = 50)
Age, median (range) years 48 (22 to 84) 43 (22 to 79) 60 (24 to 84)
Female gender, n (%) 81 (88%) 37 (88%) 44 (88%)
Disease duration, median (range) years 14 (0 to 51) 9 (0 to 29) 19 (0 to 51)
SLEDAI, median (range) 2 (0 to 16) 2 (0 to 16) 1 (0 to 13)
SLICC/ACR-DI median (range) 1 (0 to 8) 0 2 (1 to 8)
PMN 109/L median (range) 4.0 (<0.1 to 11) 3.6 (1.4 to 9.8) 4.7 (<0.1 to 11)
Disease manifestations at time of sampling, n    
Lupus headache 1 0 1
Arthritis 10 5 5
Kidney involvement (urinary cast, hematuria, proteinuria, or pyuria) 6 3 3
Rash 4 2 2
Alopecia 2 1 1
Low complement (C3 or C4) 36 21 15
Anti-double stranded DNA antibodies 18 10 8
Leukopenia 7 4 3
Treatment    
Prednisone, % (median dose of treated patients) 53 (5 mg) 60 (5 mg) 50 (6.25 mg)
Hydroxychloroquine, % (n) 59 (54) 69 (29) 50 (25)
Chloroquine phosphate, % (n) 2 (2) 2 (1) 2 (1)
Azathioprine, % (n) 24 (22) 29 (12) 20 (10)
Mycophenolate mofetil%, (n) 12 (11) 14 (6) 10 (5)
Rituximab, % (n) 2 (2) 0 (0) 4 (2)
Methotrexates, % (n) 4 (4) 5 (2) 4 (2)
Cyclosporine A, % (n) 2 (2) 0 (0) 4 (2)
  1. SLICC/ACR-DI, Systemic Lupus International Collaborative Clinics/American College of Rheumatology (ACR) damage index; SLEDAI-2 K, Systemic lupus erythematosus disease activity index 2000; PMN, polymorphonuclear leukocytes.